Stock Events

Stock Events

Regeneron Pharmaceuticals 

$721.05
827
+$18.72+2.67% Wednesday 20:14

Statistics

Day High
726.15
Day Low
702.5
52W High
812.27
52W Low
483.07
Volume
739,906
Avg. Volume
-
Mkt Cap
99.22B
P/E Ratio
17.12
Dividend Yield
0.52%
Dividend
3.76

Upcoming

20
MAY
Dividend Ex
 
4
JUN
Dividend Payment
 
18
AUG
Dividend Ex
Estimated
 
3
SEP
Dividend Payment
Estimated
 
20
NOV
Dividend Ex
Estimated
 

Dividends

0.52%Dividend Yield
Jun 26
$0.94
Mar 26
$0.94
Dec 25
$0.88
Sep 25
$0.88
Jun 25
$0.88
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
-14.55%

Earnings

30JulExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
8.22
9.78
11.33
12.89
Expected EPS
10.847155
Actual EPS
N/A

Financials

31.41%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
28.69BRevenue
9.01BNet Income

Analyst Ratings

874.39Average Price Target
The highest estimate is 1057.00.
From 18 ratings within the last 6 months. This is not an investment recommendation.
Buy
78%
Hold
22%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow REGN. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap178B
Amgen competes directly with Regeneron in the biotechnology sector, focusing on innovative therapeutics in areas like oncology and cardiovascular disease.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences is a competitor in the biopharmaceutical field, particularly in antiviral drugs, which may overlap with Regeneron's infectious disease treatments.
Abbvie
ABBV
Mkt Cap365.43B
AbbVie operates in similar therapeutic areas as Regeneron, including immunology and oncology, making it a direct competitor.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Bristol Myers Squibb competes in the biopharmaceutical space, focusing on cancer, HIV/AIDS, and cardiovascular diseases, areas that intersect with Regeneron's interests.
Pfizer
PFE
Mkt Cap149.77B
Pfizer is a global pharmaceutical company with a broad product portfolio that includes immunology and oncology drugs, competing with Regeneron's offerings.
Merck
MRK
Mkt Cap277.02B
Merck is known for its strong presence in the pharmaceutical industry, including areas like cancer treatment and infectious diseases, making it a competitor to Regeneron.
Novartis
NVS
Mkt Cap279.67B
Novartis competes with Regeneron in multiple areas, including ophthalmology and immunology, with a strong focus on research and development.
Roche
RHHBY
Mkt Cap328.49B
Roche Holding AG, through its biotech division, competes in the oncology and immunology sectors, directly challenging Regeneron's market.
Sanofi
SNY
Mkt Cap110.4B
Sanofi collaborates with Regeneron on some projects but also competes in areas like immunology and rare diseases, making the relationship complex.
Astrazeneca
AZN
Mkt Cap286.4B
AstraZeneca is involved in biopharmaceuticals across several therapeutic areas, including respiratory, cardiovascular, and oncology, competing with Regeneron.

About

There is no Profile data available for RGO.SG.
Show more...
CEO
Dr. Leonard S. Schleifer M.D., Ph.D.
Employees
15158
Country
United States
ISIN
US75886F1075

Listings

STU
DE
RGO.STU
MX
MX
REGN.MX
MU
DE
RGO.MU
VI
AT
REGN.VI

0 Comments

Share your thoughts

FAQ

What is Regeneron Pharmaceuticals stock price today?▼
The current price of REGN is $721.05 USD — it has increased by +2.67% in the past 24 hours. Watch Regeneron Pharmaceuticals stock price performance more closely on the chart.
What is Regeneron Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Regeneron Pharmaceuticals stocks are traded under the ticker REGN.
Is Regeneron Pharmaceuticals stock price growing?▼
REGN stock has risen by +1.98% compared to the previous week, the month change is a -5.16% fall, over the last year Regeneron Pharmaceuticals has showed a +28.55% increase.
What is Regeneron Pharmaceuticals market cap?▼
Today Regeneron Pharmaceuticals has the market capitalization of 99.22B
When is the next Regeneron Pharmaceuticals earnings date?▼
Regeneron Pharmaceuticals is going to release the next earnings report on July 30, 2026.
What were Regeneron Pharmaceuticals earnings last quarter?▼
REGN earnings for the last quarter are 9.47 USD per share, whereas the estimation was 8.91 USD resulting in a +6.24% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Regeneron Pharmaceuticals revenue for the last year?▼
Regeneron Pharmaceuticals revenue for the last year amounts to 28.69B USD.
What is Regeneron Pharmaceuticals net income for the last year?▼
REGN net income for the last year is 9.01B USD.
Does Regeneron Pharmaceuticals pay dividends?▼
Yes, REGN dividends are paid quarterly. The last dividend per share was 0.94 USD. As of today, Dividend Yield (FWD)% is 0.52%.
How many employees does Regeneron Pharmaceuticals have?▼
As of May 07, 2026, the company has 15,158 employees.
In which sector is Regeneron Pharmaceuticals located?▼
Regeneron Pharmaceuticals operates in the Health & Wellness sector.
When did Regeneron Pharmaceuticals complete a stock split?▼
Regeneron Pharmaceuticals has not had any recent stock splits.
Where is Regeneron Pharmaceuticals headquartered?▼
Regeneron Pharmaceuticals is headquartered in Tarrytown, United States.